Risk of Business Disruption from Natural Disasters, Accidents and Infectious Diseases
First written in FY2016. 3 of 9 entries say "Materialised", first in FY2020. Latest entry: FY2023-Q3.
Seikagaku moved to the "Worse" side of this theme in 2022, 2 years after the typical company in this theme (2020).
The whole theme swung hardest in 2020: 66 of 112 companies on the "Worse" side.
13 other companies' latest entry also says "Materialised".
- FY2023-Q3MaterialisedAnnual report
「Sales volumes of Alts in China fell sharply because of restrictions on outpatient visits and other effects of the renewed spread of COVID-19.」
The impact of restrictions on outpatient visits accompanying the renewed spread of infections continued to be reflected in a sharp decline in local sales volumes of Alts in China. - FY2023-Q1MaterialisedAnnual report
「Sales volumes of Alts in China fell sharply as the spread of COVID-19 led to lockdowns in major cities, reducing the rate of medical consultations.」
The lockdowns in major Chinese cities accompanying the renewed spread of infections and the decline in the rate of medical consultations materialised as a sharp decrease in local sales volumes. - FY2021RestatedAnnual report
「Some of the Company's clinical trials in Japan and overseas continue to be affected by the suspension of trials at medical institutions and subjects refraining from visiting trial sites.」
While the impact of COVID-19, including suspended clinical trials and subjects refraining from visiting trial sites, continued, business performance and the market were gradually recovering. - FY2021-Q3Renewed slowdown in Japan, continued recovery in the United StatesAnnual report
「In Japan, the market had been recovering since June, but had begun to slow again as of December because of the renewed spread of infections from November onward. In the United States, local sales have been recovering since mid-May, when economic activity resumed, and this trend continued through the end of the third quarter of the current fiscal year.」
Regarding the impact of COVID-19, the recovery in the Japanese market slowed again because of the renewed spread of infections, while local sales in the United States maintained their recovery trend through the end of the third quarter. - FY2021-Q2Recovery trend, but impact continuesAnnual report
「In the United States, local sales have been recovering since mid-May, when economic activity resumed, and this trend continued through the end of the second quarter of the current fiscal year.」
While the impact of COVID-19, including postponed medical procedures and fewer outpatient visits, continued, local sales in the United States began to recover from mid-May. - FY2021-Q1WorsenedAnnual report
「Consolidated net sales for the first quarter of the current fiscal year decreased 8.8% year on year to ¥6,972 million, as the pharmaceuticals business posted lower sales due to the reduction in domestic drug prices, the decline in outpatient visits accompanying the spread of COVID-19 and the postponement of non-urgent medical procedures in the United States.」
The risk of business disruption from infectious diseases was reflected in broad-based operating results, including fewer outpatient visits in Japan and overseas, postponed medical procedures in the United States and lower sales in the pharmaceuticals business. - FY2020MaterialisedAnnual report
「In addition, the Company's clinical trials have been affected by delays in enrolling subjects and the suspension of subject acceptance at some clinical trial sites, as medical institutions in Japan and overseas respond to COVID-19.」
The risk of business disruption from infectious diseases materialised in the form of delays in enrolling clinical trial subjects and the suspension of subject acceptance at clinical trial sites. - FY2017RestatedAnnual report
「If the Group's business locations and other facilities suffer extensive damage from natural disasters such as earthquakes and typhoons, accidents such as fires, or the spread of infectious diseases such as novel influenza, resulting in business disruption or interruptions to product supplies, this may affect its business performance.」
The risks of business disruption and interruptions to product supplies from natural disasters, accidents and infectious diseases are restated. - FY2016First statedAnnual report
「If the Group's business locations and other facilities suffer extensive damage from natural disasters such as earthquakes and typhoons, accidents such as fires, or the spread of novel influenza, resulting in business disruption or interruptions to product supplies, this may affect its business performance.」
Damage to business locations, suspension of product supplies and facility restoration costs are identified as business continuity risks.